The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
The in-network contracts provide coverage for insured patients in Connecticut, Maine, and New Hampshire for both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company said the agreement will make its cancer diagnostics and genomic tests available to more than 2.6 million people.
NantHealth is also planning to launch a 20,000-patient multi-arm, multi-drug trial based on profiling patients' tumors with its GPS Cancer test.
The coverage is for Paradigm's PCDx test, and will extend to all patients insured by UnitedHealthcare throughout the United States.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
Under a national agreement, UnitedHealthcare will cover the FoundationOne genomic profiling assay in patients with metastatic stage IV non-small cell lung cancer.
The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.